Emverm(Mebendazole)
AMRX
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Amneal Pharmaceuticals, Inc.
$5.8M
Medicare cost, 2024
$5.8M
Medicare cost, 2024
Medicare drug plans spent $5.8 million on Emverm (mebendazole) in 2024, for 1,732 prescriptions and refills filled by 1,363 patients. Spending rose 16% from 2023 to 2024. At about $3,365 per prescription it is a high-cost drug. California accounts for the most spending ($929,680, 16% of the total).
Medicare cost, 2024
$5.8M
+15.9% from 2023
Prescriptions
1,732
$3,365.47 per claim
Patients
1,363
1,356 prescribers
Total spending, 2024
$5.8M
$4,280.26 per patient
Questions and answers
How much does Medicare spend on Emverm?
Medicare prescription drug plans paid $5.8M for Emverm in 2024, for 1,732 prescriptions and refills to 1,363 patients (up 15.9% from 2023). The average cost per claim was $3,365.47.
Which state spends the most on Emverm?
California had the highest Medicare cost for Emverm in 2024: $930K for 214 claims, followed by Florida ($662K).
Who prescribes Emverm the most?
Christine L Green, family practice in Mountain View, CA, had the highest Medicare cost for Emverm in 2024: 23 claims costing $88K.
Who makes Emverm?
Emverm is made by Amneal Pharmaceuticals, Inc. (AMRX), listed in the Medicare spending data as Amneal Pharmace.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Emverm was $5.8M in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Emverm, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Christine L Green Mountain View, CA | Family Practice | 23 | Under 11 | $88K |
| Jay Jay M Joseph Las Vegas, NV | Nurse Practitioner | 12 | Under 11 | $44K |
| Harold B Parker Marianna, FL | Nurse Practitioner | 14 | 14 | $20K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 1,020 | 1,306 | 1,038 | $3.5M |
| 2023 | 1,225 | 1,577 | 1,226 | $5.0M |
| 2024 | 1,356 | 1,732 | 1,363 | $5.8M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Amneal Pharmace | 1,734 | $5.8M |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 791 side-effect reports named mebendazole, the active ingredient of Emverm (reports from 2004 on). 711 of them (89.9%) were serious, 58 named a death and 188 named a hospital stay. The reactions named most often were foetal exposure during pregnancy, nausea and drug ineffective. 194 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
791
41 in 2025 (-18.0% from 2024)
Serious
89.9%
711 reports
Deaths named
58
7.3% of reports
Hospital stays
188
23.8% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Emverm?
791 reports from 2004 through September 2026 named mebendazole, the active ingredient of Emverm. 711 of them (89.9%) were serious, 58 named a death and 188 named a hospital stay.
What are the most reported side effects of Emverm?
57 reports named foetal exposure during pregnancy, the reaction named most often, followed by nausea (51) and drug ineffective (45). In the last 5 years the reaction named most often was off label use (19 reports). A report can name several reactions.
How many side-effect reports named Emverm in 2025?
41 reports were received in 2025 (-18.0% from 2024). 2026 so far: 24 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Emverm caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Emverm caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
AMRX·AMRX drug pipeline - Drug approvals · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (mebendazole) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.